ACRO BIOMEDICAL CO., LTD.
3F, No.57, Luke 2nd Rd., Lujhu Dist, Kaohsiung City 82151, Taiwan
About us
Our Mission
ACRO Biomedical thrives to improve the health benefit of patients by providing with the unmet clinical need. We employ the most advanced technology in the biomedical field to ensure the utmost safety and efficacy of our medical products.
Company Profile
ACRO Biomedical was founded in June 2014 and positioned to develop and produce biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat, and non-collagenous proteins from animal tissues and organs, while leaving the intact collagen scaffolds as the biomaterial for high-end medical devices in the field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular, and neural surgery, etc.
Besides from the development of natural biomaterial scaffolds for tissue engineering, ACRO Biomedical has advanced in combining these tissue scaffolds with stem cells and/or somatic cells for human cell therapy in the field of skin regeneration and knee joint cartilage regeneration.
The ultimate goal for ACRO Biomedical is whole organ engineering for heart, liver, and kidney transplantation. We wish to recellularize the organ scaffold in vivo for autologous organ transplantation by grafting the decellularized natural organ scaffolds back into the live animal or human body.
Our Mission
ACRO Biomedical thrives to improve the health benefit of patients by providing with the unmet clinical need. We employ the most advanced technology in the biomedical field to ensure the utmost safety and efficacy of our medical products.
Company Profile
ACRO Biomedical was founded in June 2014 and positioned to develop and produce biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat, and non-collagenous proteins from animal tissues and organs, while leaving the intact collagen scaffolds as the biomaterial for high-end medical devices in the field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular, and neural surgery, etc.
Besides from the development of natural biomaterial scaffolds for tissue engineering, ACRO Biomedical has advanced in combining these tissue scaffolds with stem cells and/or somatic cells for human cell therapy in the field of skin regeneration and knee joint cartilage regeneration.
The ultimate goal for ACRO Biomedical is whole organ engineering for heart, liver, and kidney transplantation. We wish to recellularize the organ scaffold in vivo for autologous organ transplantation by grafting the decellularized natural organ scaffolds back into the live animal or human body.
Products
ABCcolla™ Collagen Bone Graft
Product Description
ABCcolla™ Collagen Bone Graft (Cancellous) is a decellularized native porcine bone graft material prepared by supercritical CO2 extraction technology, which is composed of native porcine collagen and bone matrix that are comparable to the human bone matrix. ABCcolla™ Collagen Bone Graft (Cancellous) is intended for filling and augmentation of bone voids or gaps during orthopedic surgeries. It facilitates cell attachment and improves bone regeneration and neovascularization. During the healing process, ABCcolla™ Collagen Bone Graft (Cancellous) gradually resorbs and is replenished by new bone.
Indication